Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H1 2020 - ResearchAndMarkets.com

DUBLIN--()--The "Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 1 respectively.

Furthermore, this report also reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development
  • Helocyte Biosciences Inc
  • Merck & Co Inc
  • Stadius Biopharma LLC
  • Trellis Bioscience Inc
  • VBI Vaccines Inc
  • Yaso Therapeutics Inc
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles
  • Bispecific Monoclonal Antibody to Target CD3 and Glycoprotein B for Cytomegalovirus (HHV-5) Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cytomegalovirus vaccine - Drug Profile
  • cytomegalovirus vaccine - Drug Profile
  • cytomegalovirus vaccine 1 - Drug Profile
  • Monoclonal Antibodies to Inhibit gH and gB for Cytomegalovirus Infections - Drug Profile
  • PPCM - Drug Profile
  • TRL-345 - Drug Profile
  • VBI-1501 - Drug Profile
  • VBI-1901 - Drug Profile
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Discontinued Products
  • Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 22, 2019: VBI Vaccines presents early GBM tumor response and immunologic data from part B of ongoing phase 1/2a study of VBI-1901 at the 2019 SNO Annual Meeting
  • Nov 11, 2019: VBI Vaccines to present initial phase 1/2a part B data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
  • Oct 24, 2019: VBI Vaccines to present new immuno-oncology data at the World Vaccine Congress Europe 2019
  • Sep 11, 2019: VBI to study cancer vaccine with GSK's adjuvant system
  • Jul 29, 2019: VBI Vaccines announces dosing of first recurrent GBM patient in Part B of ongoing phase 1/2a study of VBI-1901
  • Jun 04, 2019: VBI Vaccines reports data from part A of the ongoing phase 1/2a study of VBI-1901 in recurrent glioblastoma (GBM) patients at ASCO 2019
  • Apr 23, 2019: VBI Vaccines provides update on GBM program and announces upcoming conference call
  • Apr 03, 2019: VBI Vaccines announces poster presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop
  • Feb 07, 2019: VBI Vaccines announces third positive DSMB review in phase 1/2a study of VBI-1901 in recurrent GBM patients
  • Dec 20, 2018: VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate
  • Oct 24, 2018: VBI Vaccines to present initial data for VBI-1901 in recurrent glioblastoma (GBM) patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
  • Oct 02, 2018: VBI Vaccines late-breaker cytomegalovirus abstract chosen for oral presentation at IDWeek 2018
  • Sep 25, 2018: VBI Vaccines announces second positive DSMB review in phase 1/2a study of VBI-1901 in recurrent glioblastoma
  • Sep 25, 2018: VBI Vaccines announces second positive DSMB review in phase 1/2a study of VBI-1901 in recurrent glioblastoma (GBM) patients
  • May 10, 2018: VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine

Companies Mentioned

  • Helocyte Biosciences Inc
  • Merck & Co Inc
  • Stadius Biopharma LLC
  • Trellis Bioscience Inc
  • VBI Vaccines Inc
  • Yaso Therapeutics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/nmxyn5

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900